Overview

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir (DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults with current or historical failure on an integrase inhibitor (INI) containing regimen. The study will assess DTG 50mg twice daily administered initially with the current failing ART regimen but then with an optimised background ART regimen (OBR) after Day 7. The first analyses will be conducted after the last subject enrolled has completed 24 weeks. Subjects may remain on study after Week 24.

Phase:

Phase 3

Details

Lead Sponsor:

ViiV Healthcare

Collaborators:

GlaxoSmithKline
Shionogi

Treatments:

Dolutegravir
Integrase Inhibitors